RxDoctor Payments Data

Stevan Clark, MD

General Surgery · Los Angeles, CANPI 1376616227

Payments from drug & device makers

What this record shows

This record is dominated by education: $12,000 of the $15,868 with a category attached, or 75.6%. Intuitive Surgical accounts for 87.6% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $8,286 and has fallen 98.9% since, to $93 in 2025. Among general surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,868in general payments, 2019–2025

Across 45 payments — averaging $352.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$14K
  • Medtronic$862
  • Applied Medical Resources Corporation$502
  • TELA Bio, Inc.$165
  • Merck$45
  • Boston Scientific$44
  • plus $345 from 12 others

What the payments were for

  • Travel & lodging$2,92418%
  • Food & beverage$9446%
  • Education$12,00076%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,868 in reported general payments places this provider in the 95th percentile of 167 general surgery providers in California.

See all general surgery providers in California

Medicare billing

Part B allowed, 2024
$14,494
Medicare patients
44
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breo ElliptaFluticasone/Vilanterol21$11,305
JanuviaSitagliptin Phosphate12$6,438
Acetaminophen-CodeineAcetaminophen With Codeine180$5,037
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen227$4,797
Albuterol Sulfate HfaAlbuterol Sulfate43$2,324
Gabapentin93$1,790
Rosuvastatin Calcium41$786
Celecoxib15$731
Omeprazole53$703
Lacosamide11$662
Chlorthalidone26$638
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen20$606
Diclofenac Sodium21$575
Isosorbide Dinitrate13$493
Amlodipine Besylate76$487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$39$11,30521 claims
MerckJanuvia$45$6,43812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 167 general surgery providers in California.

Other general surgery in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →